利伐沙班在急性冠脉综合征抗凝治疗中的研究进展

Research Progress of Rivaroxaban in Anticoagulation Therapy of Acute Coronary Syndrome

抗血小板治疗和抗凝治疗在急性冠脉综合征的药物治疗中发挥了重要作用,现已有大量循证医学证据和临床研究证实了抗血小板治疗不可撼动的地位,但在抗凝治疗方面,口服抗凝药物治疗方案的选择尚未得到统一。新型口服抗凝药物利伐沙班是一种可逆的直接因子Ⅹa抑制剂,比传统口服抗凝药物更加方便有效,为急性冠脉综合征的抗凝治疗提供了新选择。现对利伐沙班在急性冠脉综合征抗凝治疗中的研究进展展开综述,为临床医生的个体化用药方案提供参考。

Antiplatelet therapy and anticoagulation therapy are important in the treatment of acute coronary syndrome.There are a number of clinical studies and evidence-based medical evidence to prove the importance of antiplatelet therapy,however the oral drug regimen has not yet been agreed upon.Rivaroxaban,a reversible direct Xa inhibitor,is more convenient and effective than traditional anticoagulant drugs and provides a new option for anticoagulation therapy of acute coronary syndrome.This article reviews the research progress of rivaroxaban in the treatment of acute coronary syndrome and provides a reference for the clinical practice of the individualized drug regimen.